Considering the detection of positive EGFR mutations in smokers and the survival benefits associated with targeted therapies, it is recommended that routine mutation testing be performed for all NSCLC patients, regardless of their clinical and demographic characteristics. Here, EGFR is linked to non-small cell lung carcinoma.